NO20092688L - Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering - Google Patents

Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering

Info

Publication number: NO20092688L
Authority: NO; Norway
Prior art keywords: compounds; methods; cannabinoid; antagonism; combination
Prior art date: 2006-12-20

Application number

NO20092688A

Other languages

English (en)

Norwegian (no)

Inventor

Cornelis G Kruse

Josephus H M Lange

Belal Shadid

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-20

Filing date

2009-07-15

Publication date

2009-09-16

2009-07-15 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2009-09-16 Publication of NO20092688L publication Critical patent/NO20092688L/no

Links

150000001875 compounds Chemical class 0.000 title abstract 6
230000008485 antagonism Effects 0.000 title abstract 2
102000012440 Acetylcholinesterase Human genes 0.000 title 1
108010022752 Acetylcholinesterase Proteins 0.000 title 1
229940022698 acetylcholinesterase Drugs 0.000 title 1
229930003827 cannabinoid Natural products 0.000 title 1
239000003557 cannabinoid Substances 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
238000000034 method Methods 0.000 abstract 3
208000011117 substance-related disease Diseases 0.000 abstract 3
206010013663 drug dependence Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010048650 Cholinesterase inhibition Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000009529 traumatic brain injury Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Gynecology & Obstetrics (AREA)

NO20092688A 2006-12-20 2009-07-15 Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering NO20092688L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US87580806P	2006-12-20	2006-12-20
EP06126584		2006-12-20
PCT/EP2007/064169 WO2008074816A1 (fr)	2006-12-20	2007-12-19	Composés présentant une combinaison d'antagonisme de canabinoïde-cb1 et d'inhibition d'acétylcholinestérase

Publications (1)

Publication Number	Publication Date
NO20092688L true NO20092688L (no)	2009-09-16

Family

ID=39111412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092688A NO20092688L (no)	2006-12-20	2009-07-15	Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering

Country Status (11)

Country	Link
EP (1)	EP2091939B1 (fr)
JP (1)	JP2010513395A (fr)
KR (1)	KR20090116716A (fr)
AT (1)	ATE502026T1 (fr)
AU (1)	AU2007336219A1 (fr)
CA (1)	CA2672814A1 (fr)
DE (1)	DE602007013275D1 (fr)
EA (1)	EA015249B1 (fr)
IL (1)	IL198926A (fr)
NO (1)	NO20092688L (fr)
WO (1)	WO2008074816A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010018856A1 (fr) *	2008-08-13	2010-02-18	持田製薬株式会社	Agent prophylactique/d’amélioration ou thérapeutique destiné aux maladies associées au récepteur des cannabinoïdes
WO2010079241A1 (fr) *	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
CA2788656A1 (fr)	2010-02-16	2011-08-25	Pfizer Inc.	(r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl) piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ole, agoniste partiel des recepteurs 5-ht4
EP2627323A4 (fr)	2010-10-12	2014-03-12	Univ Johns Hopkins	Compositions antitussives comprenant de la mémantine
JP6762930B2 (ja) *	2014-05-09	2020-09-30	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用
EP3771713A1 (fr)	2019-08-01	2021-02-03	Julius-Maximilians-Universität Würzburg	Stimulateur de sous-type 2 de récepteur cannabinoïde inhibant l'acétylcholinestérase et la butyrylcholinestérase
CN112409335B (zh) *	2020-11-04	2021-10-19	宁波大学	一种1,2,3,4-四氢吖啶-9-胺类化合物及其制备方法和用途
ES2947188T3 (es) *	2020-11-18	2023-08-02	Fundacion Del Hospital Nac De Paraplejicos Para La Investigacion Y La Integracion Fuhnpaiin	Uso de antagonistas y/o agonistas inversos de receptores CB1 para la preparación de medicamentos para tratar el síndrome de fatiga posviral

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005037199A2 (fr) *	2003-10-10	2005-04-28	Bristol-Myers Squibb Company	Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
ATE405551T1 (de) *	2004-05-28	2008-09-15	Solvay Pharm Bv	Tetrasubstituierte imidazolderivate als cannabinoid-cb1-rezeptormodulatoren mit hoher cb1-/cb2-rezeptorsubtyp-selektivität

2007
- 2007-12-19 KR KR1020097015238A patent/KR20090116716A/ko not_active Withdrawn
- 2007-12-19 WO PCT/EP2007/064169 patent/WO2008074816A1/fr not_active Ceased
- 2007-12-19 AU AU2007336219A patent/AU2007336219A1/en not_active Abandoned
- 2007-12-19 AT AT07857792T patent/ATE502026T1/de not_active IP Right Cessation
- 2007-12-19 EP EP07857792A patent/EP2091939B1/fr active Active
- 2007-12-19 CA CA002672814A patent/CA2672814A1/fr not_active Abandoned
- 2007-12-19 JP JP2009542038A patent/JP2010513395A/ja not_active Withdrawn
- 2007-12-19 DE DE602007013275T patent/DE602007013275D1/de active Active
- 2007-12-19 EA EA200970596A patent/EA015249B1/ru not_active IP Right Cessation
2009
- 2009-05-25 IL IL198926A patent/IL198926A/en not_active IP Right Cessation
- 2009-07-15 NO NO20092688A patent/NO20092688L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2007336219A1 (en)	2008-06-26
IL198926A (en)	2013-03-24
EA200970596A1 (ru)	2010-02-26
IL198926A0 (en)	2010-02-17
JP2010513395A (ja)	2010-04-30
EP2091939B1 (fr)	2011-03-16
WO2008074816A1 (fr)	2008-06-26
CA2672814A1 (fr)	2008-06-26
KR20090116716A (ko)	2009-11-11
EP2091939A1 (fr)	2009-08-26
ATE502026T1 (de)	2011-04-15
DE602007013275D1 (de)	2011-04-28
EA015249B1 (ru)	2011-06-30

Legal Events

Date	Code	Title	Description
2012-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20092688L (no)	2009-09-16	Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering
UA94660C2 (en)	2011-05-25	Amino-heterocyclic compounds
MY141229A (en)	2010-03-31	Piperidine-benzenesulfonamide derivatives
EA200970310A1 (ru)	2009-10-30	Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht
MY155318A (en)	2015-09-30	Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
ATE455763T1 (de)	2010-02-15	Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
MX2009005509A (es)	2009-06-03	2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
MY149422A (en)	2013-08-30	5-(arylsulfonyl)-pyrazolopiperidines
TW200633957A (en)	2006-10-01	Compounds
UA100232C2 (uk)	2012-12-10	Кристалічні форми інгібітора glyt1
NO20075477L (no)	2007-12-13	Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
MX2010009643A (es)	2010-09-22	Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
MX2016001080A (es)	2016-06-21	Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
GB0428232D0 (en)	2005-01-26	Compounds
MX2009006889A (es)	2009-07-07	Compuestos con una combinacion de antagonismo de cannabinoide-receptor cannabinoide subtipo 1 e inhibicion de acetilcolinesterasa.
MY136718A (en)	2008-11-28	Sulfonamide compounds for the treatment of neurodegenerative disorders
PT1745010E (pt)	2009-11-10	Derivados de ciclo-hexil-1,4-diamina substituídos
UA88910C2 (ru)	2009-12-10	Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения
MX2010008239A (es)	2010-08-18	2-aminoquinolinas.
MX2010009820A (es)	2010-10-15	2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.
WO2006039767A8 (fr)	2007-06-14	Derives de piperidine, compositions pharmaceutiques les contenant et procedes pour les preparer
ATE423093T1 (de)	2009-03-15	Neue mao-b-hemmer
EA201070019A1 (ru)	2010-06-30	4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
UA98122C2 (ru)	2012-04-25	Производные сульфонилпиразол и сульфонилпиразолон карбоксамидина как антагонисты рецепторов 5-ht6
TN2010000432A1 (en)	2011-12-29	New compounds for the treatment of cns disorders